A Swedish innovative, patented and unique cancer

Potentially effective on all cancer types with solid tumours draining through the lymphatic system (>90 % of global cancer incidence)
Based on the patient’s own immune system
Very promising, early clinical results
Photo: Thomas Lundquist
No significant side effects
Autologous treatment
113 patients treated so far (October-09)

Broad potential product portfolio

Single 1st line treatment

Combination treatment w. standard chemotherapy

Adjuvant treatment


Address:Lfstrms Allé 5A SE-172 66 SUNDBYBERG SWEDEN  
Email:info@sinorda.com  
Copyright © 2020- SentoClone International AB   All Rights Reserved.